MA45863A - Agent arni contre l'infection par le virus de l'hépatite b - Google Patents

Agent arni contre l'infection par le virus de l'hépatite b

Info

Publication number
MA45863A
MA45863A MA045863A MA45863A MA45863A MA 45863 A MA45863 A MA 45863A MA 045863 A MA045863 A MA 045863A MA 45863 A MA45863 A MA 45863A MA 45863 A MA45863 A MA 45863A
Authority
MA
Morocco
Prior art keywords
arni
infection
agent against
against hepatitis
hepatitis
Prior art date
Application number
MA045863A
Other languages
English (en)
Inventor
Lauren J Almeida
Bruce D Given
David L Lewis
Zhen Li
Tao Pei
David B Rozema
Darren H Wakefield
Christine I Wooddell
Rui Zhu
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MA45863A publication Critical patent/MA45863A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MA045863A 2016-08-04 2017-08-04 Agent arni contre l'infection par le virus de l'hépatite b MA45863A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370754P 2016-08-04 2016-08-04
US201762534733P 2017-07-20 2017-07-20
US201762540639P 2017-08-03 2017-08-03

Publications (1)

Publication Number Publication Date
MA45863A true MA45863A (fr) 2019-06-12

Family

ID=61073185

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045863A MA45863A (fr) 2016-08-04 2017-08-04 Agent arni contre l'infection par le virus de l'hépatite b

Country Status (22)

Country Link
US (5) US10780108B2 (fr)
EP (2) EP4364808A2 (fr)
JP (3) JP7237816B2 (fr)
KR (4) KR102540359B1 (fr)
CN (2) CN116514890A (fr)
AU (2) AU2017306692B2 (fr)
BR (1) BR112019002117A2 (fr)
CA (2) CA3229270A1 (fr)
CL (4) CL2019000278A1 (fr)
CO (1) CO2019002017A2 (fr)
CR (3) CR20220469A (fr)
EC (1) ECSP19015395A (fr)
IL (2) IL305507A (fr)
JO (2) JOP20170161A1 (fr)
MA (1) MA45863A (fr)
MX (3) MX2019001493A (fr)
PE (1) PE20190567A1 (fr)
PH (1) PH12019500245A1 (fr)
SG (2) SG10201913585SA (fr)
TW (1) TW202334420A (fr)
UY (1) UY37353A (fr)
WO (1) WO2018027106A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113430196A (zh) 2011-06-30 2021-09-24 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
CA2991639A1 (fr) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Therapie par interference arn pour l'infection par le virus de l'hepatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR102634762B1 (ko) 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도
RS63836B1 (sr) 2017-04-05 2023-01-31 Silence Therapeutics Gmbh Proizvodi i sastavi
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
JP7353276B2 (ja) 2017-10-20 2023-09-29 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎感染の治療方法
TN2020000059A1 (en) 2017-11-01 2022-01-06 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CN110944675A (zh) 2017-12-01 2020-03-31 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
WO2019105414A1 (fr) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation associés
WO2019105419A1 (fr) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Acide nucléique, composition et conjugué le contenant, procédé de préparation et utilisation
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
MX2021001056A (es) 2018-08-13 2021-04-12 Alnylam Pharmaceuticals Inc Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
EP3842534A4 (fr) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. Acide nucléique, composition et conjugué contenant un acide nucléique et leur procédé d'utilisation
EP3862024A4 (fr) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. Conjugué d'arn interférent court, son procédé de préparation et utilisation associée
HRP20231338T1 (hr) * 2018-12-20 2024-02-16 Vir Biotechnology, Inc. Kombinirana terapija hbv
WO2020163747A1 (fr) * 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Agents arni contre l'infection par le virus de l'hépatite b
US20200332297A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
MA55720A (fr) * 2019-04-18 2022-02-23 Janssen Pharmaceuticals Inc Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
WO2020255008A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (hbv) et d'arni ciblant le hbv
CN114340664A (zh) * 2019-06-18 2022-04-12 爱尔兰詹森科学公司 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
CN110218728A (zh) * 2019-06-28 2019-09-10 厦门甘宝利生物医药有限公司 一种新化合物及其应用
US20240033278A9 (en) * 2020-06-10 2024-02-01 Medshine Discovery Inc. Conjugate group and conjugate
JP2023531682A (ja) * 2020-06-22 2023-07-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｄ型肝炎ウイルス感染の処置のための組成物および方法
KR20230066587A (ko) 2020-09-11 2023-05-16 애로우헤드 파마슈티컬스 인코포레이티드 치료제의 전달을 위한 지질 접합체
TW202227102A (zh) 2020-09-22 2022-07-16 瑞典商阿斯特捷利康公司 治療脂肪肝病之方法
WO2022078479A1 (fr) * 2020-10-16 2022-04-21 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
CN116916935A (zh) * 2020-12-18 2023-10-20 奥利克斯医药有限公司 抑制乙型肝炎病毒表达的RNAi制剂以及其用途
WO2022133230A1 (fr) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
WO2022152869A1 (fr) * 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Utilisation d'oligonucléotides pour des individus présentant une déficience hépatique
CN117858949A (zh) * 2021-05-28 2024-04-09 箭头药业股份有限公司 用于抑制粘蛋白5AC(MUC5AC)的表达的RNAi试剂、其组合物及其使用方法
WO2023233290A1 (fr) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Agents d'arni ciblant pd-l1
WO2023246750A1 (fr) * 2022-06-21 2023-12-28 正大天晴药业集团股份有限公司 Acide ribonucléique double brin pour inhiber le virus de l'hépatite b
WO2024015796A1 (fr) * 2022-07-11 2024-01-18 Sanegene Bio Usa Inc. Dérivés du ribose modifié en 2' optimisés et procédés d'utilisation

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
EP0942000B1 (fr) 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. Oligonucléotides modifiés en position 2'
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
ATE239484T1 (de) 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
EP0577558A2 (fr) 1992-07-01 1994-01-05 Ciba-Geigy Ag Nucléosides carbocycliques contenant des noyaux bicycliques, oligonucléotides en dérivant, procédé pour leur préparation, leur application et des intermédiaires
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
AU6412794A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5856459A (en) 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
AU6430599A (en) 1998-10-09 2000-05-01 Cytogenix, Inc. Enzymatic synthesis of ssdna
US5977341A (en) 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
WO2000053722A2 (fr) 1999-03-10 2000-09-14 Phogen Limited Administration de substances a des cellules
DK1102785T3 (da) 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
US7019113B2 (en) 1999-06-07 2006-03-28 Mirus Bio Corporation Reversible modification of membrane interaction
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
WO2003070918A2 (fr) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Inhibition mediee par interference arn d'une expression genique faisant appel a des acides nucleiques interferants courts chimiquement modifies (sina)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
CA2442092A1 (fr) 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Inhibition regulee par des oligonucleotides de la replication du virus de l'hepatite b et du virus de l'hepatite c
US9994853B2 (en) * 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1627061B1 (fr) 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. Interference arn a mediation assuree par l'inhibition de genes au moyen de petit acide nucleique interferent (ansi) modifie chimiquement
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US6635428B2 (en) 2001-12-04 2003-10-21 Quest Diagnostics Investments Incorporated Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
EP2221377B2 (fr) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucletides double brin
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP2258847B2 (fr) 2002-08-05 2020-07-01 Silence Therapeutics GmbH Autres nouvelles formes de molécules d'ARN interférant
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003290598A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
WO2005009346A2 (fr) 2003-06-24 2005-02-03 Mirus Corporation Inhibition d'une fonction genique par distribution in vivo d'inhibiteurs d'expression genique a base de polynucleotides dans des cellules mammiferes
WO2005021751A1 (fr) 2003-09-01 2005-03-10 Patrick Arbuthnot Cassette d'expression d'arn à traitement automatique
JP2007520461A (ja) 2003-12-16 2007-07-26 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 肝炎ウイルスの負荷を変えるための方法および化合物
WO2005065719A1 (fr) 2004-01-12 2005-07-21 Genesense Technologies Inc. Oligonucleotides antisens diriges contre la ribonucleotide reductase r2 et utilisation de ceux-ci dans des polytherapies destinees au traitement du cancer
EP1742958B1 (fr) 2004-03-15 2017-05-17 City of Hope Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin
EP1752536A4 (fr) 2004-05-11 2008-04-16 Alphagen Co Ltd Polynucleotide provoquant l'interference rna et procede de regulation d'expression genetique avec l'usage de ce dernier
WO2006017932A1 (fr) 2004-08-18 2006-02-23 Genesense Technologies Inc. Molecules de petit arn interferant dirigees contre la ribonucleotide reductase et ses utilisations
CN101142316A (zh) 2005-03-09 2008-03-12 牧岩生命工学研究所 小干扰rna和包含它的用于治疗乙型肝炎的药物组合物
DK1866414T3 (da) 2005-03-31 2012-04-23 Calando Pharmaceuticals Inc Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf.
CN101426912A (zh) 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
RU2418068C2 (ru) 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
CA2619876A1 (fr) 2005-08-17 2007-02-22 Sirna Therapeutics, Inc. Molecules d'acide nucleique interferent court chimiquement modifiees induisant l'interference de l'arn
US20070197460A1 (en) 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
CN100447243C (zh) 2005-11-15 2008-12-31 中国人民解放军第四军医大学 HBV特异性干涉靶位点基因及其siRNA和其在抗HBV感染中的应用
CN101024088A (zh) 2006-02-20 2007-08-29 桂林医学院 抗乙型肝炎病毒微小核糖核酸干扰分子及其设计方法
WO2008119000A1 (fr) 2007-03-27 2008-10-02 University Of Iowa Research Foundation Inactivation des génomes viraux, à médiation par une nucléase à doigt de zinc et une interférence arn
US8877917B2 (en) 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
CN101755049B (zh) 2007-05-29 2014-03-12 约翰内斯堡威特沃特斯兰德大学 初级微rna表达盒
KR20100069679A (ko) 2007-09-17 2010-06-24 재단법인 목암생명공학연구소 ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법
WO2009045457A2 (fr) 2007-10-02 2009-04-09 Rxi Pharmaceuticals Corp. CONSTRUCTIONS D'ARNi À STRUCTURE TRIPARTITE
WO2009082607A2 (fr) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Lipides de ciblage
WO2009126933A2 (fr) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Délivrance spécifique à un site d'acides nucléiques en combinant des ligands de ciblage avec des composants endosomolytiques
CN101603042B (zh) 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
CN101322847A (zh) 2008-06-23 2008-12-17 淮安市第四人民医院 基于siRNA池干扰的复合载体介导的抗乙肝病毒基因药物
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
CA3151965A1 (fr) 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Agents allonges servant de substrats de dicer et procedes d'inhibition specifique de l'expression d'un gene
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
US9012225B2 (en) 2009-05-05 2015-04-21 Miragen Therapeutics Lipophilic polynucleotide conjugates
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
US9050375B2 (en) 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
WO2011100131A2 (fr) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomères et oligonucléotides comprenant un ou plusieurs adduits de cycloaddition
MX2012009178A (es) 2010-02-24 2012-11-30 Arrowhead Res Corp Composiciones para liberacion dirigida de arnsi.
EP2390327A1 (fr) 2010-05-27 2011-11-30 Sylentis S.A. ARNsi et leur utilisation dans des procédés et des compositions pour le traitement et/ou la prévention de maladies oculaires
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2616543A1 (fr) 2010-09-15 2013-07-24 Alnylam Pharmaceuticals, Inc. Agents à base d'arni modifiés
CN101948834B (zh) 2010-09-16 2012-07-04 山东大学 用于治疗HBV的siRNA
PL3124610T3 (pl) 2010-10-28 2019-09-30 Benitec Biopharma Limited Leczenie hbv
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
BR122020024388B1 (pt) 2010-12-29 2021-09-21 F. Hoffmann-La Roche Ag Oligonucleotídeo e composição farmacêutica
RU2667524C2 (ru) 2011-04-21 2018-09-21 Ионис Фармасьютикалз, Инк. Модулирование экспрессии вируса гепатита b (hbv)
EP2709989B8 (fr) 2011-05-18 2018-04-18 Janssen Sciences Ireland UC Dérivés de quinazoline pour le traitement des infections virales et d'autres maladies
CN113430196A (zh) 2011-06-30 2021-09-24 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013032829A1 (fr) 2011-08-26 2013-03-07 Arrowhead Research Corporation Polymères poly(ester vinyliques) pour administration d'acide nucléique in vivo
KR20220045091A (ko) 2011-11-18 2022-04-12 알닐람 파마슈티칼스 인코포레이티드 트랜스티레틴（ＴＴＲ） 관련 질병을 치료하기 위한 ＲＮＡｉ 제제, 조성 및 그의 사용방법
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
WO2013159109A1 (fr) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation de l'expression du virus de l'hépatite b (hbv)
US9212363B2 (en) 2012-05-11 2015-12-15 City Of Hope RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN103333890B (zh) 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 治疗乙型病毒性肝炎的rna干扰制剂
WO2015042447A1 (fr) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Nucléosides thérapeutiques ciblées et leur utilisation
WO2015050871A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Composés organiques destinés au traitement du virus de l'hépatite b
EP4223315A3 (fr) 2014-05-01 2023-08-23 Ionis Pharmaceuticals, Inc. Procédé de synthèse de grappes de conjugués réactifs
CN104059916A (zh) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 乙肝病毒特异性的microRNA样siRNA序列及其用途
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
CN108136206B (zh) 2015-07-17 2021-10-15 阿克丘勒斯治疗公司 抗乙型肝炎病毒的组合物和药剂及其用途
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
CA2991639A1 (fr) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Therapie par interference arn pour l'infection par le virus de l'hepatite b
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
MA45478A (fr) 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
EP3506913A4 (fr) 2016-09-02 2020-06-10 Arrowhead Pharmaceuticals, Inc. Ligands de ciblage
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2020163747A1 (fr) 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Agents arni contre l'infection par le virus de l'hépatite b
US20200332297A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
MX2021013698A (es) 2019-05-13 2021-12-10 Vir Biotechnology Inc Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb).
CN114340664A (zh) 2019-06-18 2022-04-12 爱尔兰詹森科学公司 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
KR20230050328A (ko) 2020-07-08 2023-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv에 대한 rna 레플리콘 백신
WO2022133230A1 (fr) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une infection par le virus de l'hépatite b

Also Published As

Publication number Publication date
JP2019527694A (ja) 2019-10-03
US10780108B2 (en) 2020-09-22
MX2020011805A (es) 2020-12-07
CA3032945A1 (fr) 2018-02-08
AU2017306692A1 (en) 2019-02-21
KR102540359B1 (ko) 2023-06-02
SG11201900910TA (en) 2019-02-27
AU2022205929A1 (en) 2022-10-06
PH12019500245A1 (en) 2019-10-14
IL264575B2 (en) 2024-02-01
JP7237816B2 (ja) 2023-03-13
NZ750390A (en) 2023-11-24
CR20190056A (es) 2019-05-20
US20220079973A1 (en) 2022-03-17
TW202018081A (zh) 2020-05-16
WO2018027106A2 (fr) 2018-02-08
ECSP19015395A (es) 2019-06-30
TW202334420A (zh) 2023-09-01
KR102650107B1 (ko) 2024-03-20
US20190255091A1 (en) 2019-08-22
SG10201913585SA (en) 2020-02-27
KR20190038606A (ko) 2019-04-08
JOP20170161A1 (ar) 2019-01-30
IL264575A (en) 2019-02-28
MX2019001493A (es) 2019-07-12
US11590156B2 (en) 2023-02-28
IL264575B1 (en) 2023-10-01
US11517584B2 (en) 2022-12-06
EP4364808A2 (fr) 2024-05-08
CN109843902A (zh) 2019-06-04
JP2023123469A (ja) 2023-09-05
KR20240039232A (ko) 2024-03-26
KR20230025949A (ko) 2023-02-23
CL2021001195A1 (es) 2021-10-22
CL2022001478A1 (es) 2023-01-13
CL2019000278A1 (es) 2020-03-20
CN109843902B (zh) 2023-05-30
US20230355651A1 (en) 2023-11-09
US20210100829A1 (en) 2021-04-08
CR20220468A (es) 2023-05-12
KR20230084607A (ko) 2023-06-13
US20190292547A1 (en) 2019-09-26
CA3229270A1 (fr) 2018-02-08
CR20220469A (es) 2022-10-26
MX2020011806A (es) 2020-12-07
EP3494123A2 (fr) 2019-06-12
BR112019002117A2 (pt) 2019-07-09
EP3494123A4 (fr) 2020-07-22
JP2022068222A (ja) 2022-05-09
PE20190567A1 (es) 2019-04-22
UY37353A (es) 2018-02-28
CN116514890A (zh) 2023-08-01
JOP20190015A1 (ar) 2019-02-04
WO2018027106A3 (fr) 2018-03-15
AU2017306692B2 (en) 2022-08-04
KR102500675B1 (ko) 2023-02-15
IL305507A (en) 2023-10-01
CL2020002156A1 (es) 2020-12-18
CO2019002017A2 (es) 2019-05-31

Similar Documents

Publication Publication Date Title
MA45863A (fr) Agent arni contre l'infection par le virus de l'hépatite b
HK1251219A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的6，7-二氫吡啶並[2，1-a]酞嗪-2-酮類化合物
MA50813A (fr) Vaccins contre le virus d'epstein-barr
HK1255847A1 (zh) 針對乙型肝炎病毒的疫苗
EP3325097A4 (fr) Compositions et agents contre le virus de l'hépatite b et utilisations de ceux-ci
EP3426633A4 (fr) Élimination du virus de l'hépatite b par des agents antiviraux
EP3332007A4 (fr) Thérapie par interférence arn pour l'infection par le virus de l'hépatite b
DK3400291T3 (da) Manipuleret virus
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
EP3139954A4 (fr) Méthodes et compositions pour traiter les infections par le virus de l'hépatite b
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
DK3137078T3 (da) Behandling af hepatitis delta-virusinfektion
DK3370723T3 (da) Behandling af hepatitis delta-virusinfektion
EP3463469C0 (fr) Combinaision de ledipasvir et sofosbuvir pour l'utilisation dans le traitement de l'hepatite b chez l'homme
WO2014160088A3 (fr) Traitement d'infections par le virus de l'hépatite b
EP3473639A4 (fr) Inhibiteur du virus de l'hépatite c et application
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201702193D0 (en) Hepatitis E virus vaccine
EP3445367A4 (fr) Inhibiteurs du virus de l'hépatite c
TH1501001789A (th) อนุพันธ์ของ 1,2,4-ไตรอะซีน สำหรับการบำบัดของโรคติดเชื้อไวรัส
TH1601001266A (th) วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b
AU2015900546A0 (en) Agents and methods for inhibiting virus infection
TH1501006890A (th) อนุพันธ์ไพริโดนสำหรับการบำบัดการติดเชื้อไวรัสและโรคอื่นเพิ่มเติม